| Title | Prescription of fondaparinux in hospitalised patients. | | Author(s) | Baroletti S, Labreche M, Niles M, Fanikos J, Goldhaber SZ | | Institution | Department of Pharmacy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. E-mail: sbaroletti@partners.org. | | Source | Thromb Haemost 2009 Jun; 101(6):1091-4. | | Abstract | Fondaparinux is an antithrombotic agent with unique properties that may offer benefit to patients beyond the current approved indications. To explore the off-label use versus approved use of fondaparinux, we initiated a single-center registry of fondaparinux use. During the 25-month study period, 219 patients were prescribed fondaparinux: 157 (71.7%) for prophylaxis and 62 (28.3%) patients for the treatment of thrombosis. When fondaparinux was used for prophylaxis in our registry, 94% of patients had documentation of heparin-induced thrombocytopenia (HIT). Fondaparinux warrants further evaluation in patients with HIT or suspected HIT. In the meantime, its off-label use may exceed its use for FDA-approved indications. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 19492152 |
|
